Sphingolipids occupy a peculiar position in cell biology. They are simultaneously building blocks and messengers. Ceramide, the central molecule of the sphingolipid pathway, is a well-established promoter of apoptosis, the programmed self-destruction of cells. Its breakdown products, sphingosine and sphingosine-1-phosphate, act in the opposite direction, supporting cell survival, proliferation, and differentiation. The balance among these metabolites, maintained by a network of enzymes that synthesize, degrade, and interconvert them, is therefore critical for any tissue undergoing constant cellular renewal. Few tissues fit that description better than the testis, where spermatogenesis demands the precisely choreographed proliferation, differentiation, and selective elimination of germ cells on a continuous cycle. Disrupting this balance, the researchers reasoned, could plausibly underlie the spermatogenic collapse seen in NOA.

To test this hypothesis, the team took a two-pronged approach that combined human data with experimental validation. First, they mined a publicly available microarray dataset, GSE9210, comprising testicular tissue samples from 11 patients with obstructive azoospermia and 47 patients with non-obstructive azoospermia. Because OA patients produce sperm normally, their tissue serves as a useful benchmark for intact spermatogenesis. By screening the transcriptomic data for genes involved in sphingolipid metabolism, the researchers identified 23 such genes that were differentially expressed between the OA and NOA groups. This bioinformatic screen provided the human evidence that sphingolipid biology is systematically altered when sperm production fails, but it could not, on its own, establish whether those changes are a cause or a consequence of the condition.

For that, the researchers turned to a busulfan-induced mouse model. Busulfan is a chemotherapeutic alkylating agent that selectively depletes spermatogonial stem cells and is widely used to generate animals with impaired spermatogenesis. The team treated mice with busulfan and compared their testes with those of untreated controls, eight animals per group. Using quantitative real-time PCR to measure gene expression, immunohistochemistry to localize protein changes within the testicular architecture, and high-performance liquid chromatography (HPLC) to quantify individual lipid metabolites, the researchers assembled a multi-layered picture of what happens to sphingolipid metabolism when the seminiferous tubules are devastated.

The gene expression results were striking. In the busulfan-treated testes, a cohort of genes responsible for breaking down ceramide and building downstream sphingolipids was significantly downregulated. These included Asah1 and Asah2, which encode ceramidases that convert ceramide into sphingosine; Acer1 and Acer2, additional alkaline ceramidases; Cerk, which phosphorylates ceramide toward ceramide-1-phosphate; Elovl1, an elongase that manufactures the very-long-chain fatty acids needed for ceramide synthesis; Sgms1, which produces sphingomyelin from ceramide; and Galc, a galactosidase involved in glycosphingolipid turnover. In parallel, the three sphingomyelinase genes Smpd1, Smpd2, and Smpd3, which cleave sphingomyelin back into ceramide, were significantly upregulated. The overall pattern suggested a metabolic shift favoring ceramide accumulation and sphingolipid depletion, a combination that would be expected to push germ cells toward apoptosis.

The HPLC measurements confirmed that the enzymatic shifts were mirrored by real changes in the lipid pool itself. Levels of four ceramide species, Cer14, Cer16, Cer18, and Cer20, along with sphingosine and sphingosine-1-phosphate, were all significantly reduced in the busulfan-treated testes. The concurrent decline of both pro-apoptotic ceramides and pro-survival sphingosine-1-phosphate may seem paradoxical, but it points to a wholesale collapse of the sphingolipid metabolic network rather than a simple tipping of the balance in one direction. When the machinery for both generating and recycling these lipids is impaired, the fine-grained control over germ cell fate that depends on them is lost, depriving the seminiferous epithelium of signals needed to sustain the delicate sequence of spermatogenic stages.

The immunohistochemical findings connected this metabolic disarray to the inflammatory and cell-death pathways that characterize testicular damage. Busulfan-treated testes showed increased expression of matrix metalloproteinases MMP-2 and MMP-9, enzymes associated with tissue remodeling and inflammation, together with elevated levels of cleaved caspase-3, the executioner enzyme of apoptosis. At the same time, Bcl-2, a key anti-apoptotic protein that normally protects germ cells from premature death, was reduced. All of these changes reached statistical significance. Together they depict a tissue in which the anti-apoptotic safety net has been withdrawn, the apoptotic machinery has been activated, and inflammatory remodeling is underway, a scenario consistent with the loss of germ cells that defines NOA.

The study builds on earlier evidence that individual sphingolipid enzymes are indispensable for male fertility. Sphingomyelin synthase 1, for example, has been shown to be essential for male fertility in mice, and sphingosine-1-phosphate has been demonstrated to inhibit germ cell apoptosis in the human testis. What distinguishes the new work is its systems-level scope: rather than examining one enzyme in isolation, it maps coordinated changes across dozens of genes and multiple metabolite classes, and it anchors those changes in human disease data rather than relying solely on animal models. The convergence of the human bioinformatic screen and the mouse validation significantly strengthens the argument that sphingolipid dysregulation is not an incidental byproduct of testicular damage but a mechanistically relevant feature of spermatogenic failure.

Caveats remain, as they do in any translational study. The busulfan model reproduces the germ cell depletion of NOA but not necessarily its full range of causes, which in patients include genetic defects, hormonal disturbances, and environmental exposures. Correlation between sphingolipid changes and spermatogenic collapse does not yet prove causation, and the specific sequence of events, whether lipid dysregulation triggers apoptosis or follows it, requires targeted interventional studies. Nevertheless, the identification of concrete molecular targets opens tangible therapeutic avenues. If restoring ceramidase activity, sphingomyelin balance, or sphingosine-1-phosphate signaling could rescue germ cells in damaged testes, sphingolipid-modulating drugs, some of which already exist in other therapeutic areas, might one day help men with NOA regain at least partial sperm production.

The broader significance of the findings extends beyond a single diagnosis. Male factor infertility contributes to roughly half of infertile couples, yet in many cases the underlying biology remains unexplained, and treatment options are limited to assisted reproduction rather than genuine restoration of spermatogenesis. By implicating an entire metabolic pathway that is druggable in principle, the study reframes NOA not merely as a developmental dead end but as a potentially correctable biochemical state. The research, supported in part by the Iran National Science Foundation, adds sphingolipid metabolism to the growing list of lipid-mediated processes, alongside steroidogenesis and membrane remodeling, that must be intact for sperm production to proceed. Future work will need to determine whether the same metabolic signature appears in larger patient cohorts and whether pharmacological correction of the pathway can translate into restored fertility, but the study offers something the field has lacked: a specific, measurable, and modifiable molecular axis on which to focus the search for therapies against one of the most challenging forms of male infertility.

Subject of Research: Sphingolipid metabolism dysregulation in non-obstructive azoospermia

Article Title: Dysregulation of Sphingolipid Metabolism in Non-Obstructive Azoospermia: Insights from Bioinformatics and a Busulfan-Induced Mouse Model

Article References: Parvini, M., Ghasemian, F., & Salimy, S. (2026). Dysregulation of Sphingolipid Metabolism in Non-Obstructive Azoospermia: Insights from Bioinformatics and a Busulfan-Induced Mouse Model. Reproductive Sciences. https://doi.org/10.1007/s43032-026-02194-5

Image Credits: AI Generated

DOI: 10.1007/s43032-026-02194-5

Keywords: sphingolipids, ceramide, sphingosine-1-phosphate, azoospermia, spermatogenesis, male infertility, busulfan, apoptosis, testis, reproductive biology, HPLC, bioinformatics